This has reference to our letter dated January 16 2025.1) The Board has considered and approved the unaudited Consolidated & Standalone Financial Results of the company, for the Quarter ended 31.12.2024 in accordance with the Indian Accounting Standards (IND-AS) as per Companies (Indian Accounting Standards) Rules, 2015.2) Limited Review Report on the Unaudited Standalone and Consolidated Financial Results of the Company, for the quarter ended 31.12.2024 has also been approved.3) The Board has discussed and approved a funding proposal to raise funds on asecuritized basis to address the pressing demands on the company and passedappropriate resolution to move the proposal forward.The meeting commenced at 11:00 a.m. and concluded at 12:25 p.m.
Board Meeting Outcome for Outcome Of Board Meeting - Scrip Code 526139
Filed with BSE · · 10 pages · English
Release
Transgene Biotek Limited on 6ix
Earlier from Transgene Biotek
- Transgene Biotek Limited. Press Release Jan 20 2025
- Statement Of Deviation & Variation
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Transgene Biotek Limited. Press Release Jan 16 2025
- Board Meeting Intimation for Intimation Of The Board Meeting To Be Held On Friday, 24"January 2025
Later from Transgene Biotek
- The Board Has Considered And Approved The Unaudited Consolidated & Standalone Financial Results Of The Company, For The Quarter Ended 31.12.2024 In Accordance With The Indian Accounting Standards (IND-AS) As Per Companies (Indian Accounting Standards
- Transgene Biotek Limited. Press Release Jan 24 2025
- Announcement under Regulation 30 (LODR)-Newspaper Publication
- Transgene Biotek Limited. Press Release Feb 12 2025
- Integrated Filing (Financial)
Follow Transgene Biotek into a list and get an email when it puts out news.
Follow Transgene Biotek